Literature DB >> 35138571

Fibrosing Interstitial Lung Disease in Children: An HRCT-Based Analysis.

Deeksha Bhalla1, Manisha Jana2, Priyanka Naranje1, Ashu Seith Bhalla1, Sushil K Kabra3.   

Abstract

OBJECTIVE: To determine high resolution CT (HRCT) patterns of pulmonary fibrosis (PF) in children; and their etiological correlates.
METHODS: This was a retrospective study involving 149 children with diffuse lung disease (DLD). Patterns of involvement were classified based on dominant lung finding as ground glass opacity (GGO) dominant, nodule dominant, cystic lung disease, or PF. Patterns of PF were classified based on distribution and morphology into airway centric fibrosis (ACF), subpleural fibrosis (SPF), progressive massive fibrosis (PMF) and fibrocavitary. A comparison was made between the two dominant groups for apicobasal distribution, associated findings (GGO, nodules, cysts), and pulmonary artery hypertension (PAH).
RESULTS: Nineteen patients showed PF on HRCT. ACF was commonest (52.6%), followed by SPF (42.1%). The common etiology was sarcoidosis (30%) in ACF, and connective tissue disorders (CTD) (50%) in SPF. Significant difference was found between ACF and SPF in apicobasal distribution (p = 0.04), presence of nodules (p = 0.03), and cysts (p = 0.02).
CONCLUSION: PF may present as an end stage of several childhood lung diseases. PF on imaging has discernible morphological patterns that correlate with underlying etiology.
© 2022. Dr. K C Chaudhuri Foundation.

Entities:  

Keywords:  Fibrosis; Interstitial; Lung diseases; Pediatrics; Sarcoidosis; Tomography; X-ray computed

Year:  2022        PMID: 35138571     DOI: 10.1007/s12098-021-04004-z

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  1 in total

1.  Airway-centered interstitial fibrosis - an under-recognized subtype of diffuse parenchymal lung diseases.

Authors:  E Silbernagel; A Morresi-Hauf; S Reu; B King; W Gesierich; M Lindner; J Behr; F Reichenberger
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.